Seja a primeira pessoa a gostar disto
This report provides comprehensive information on the current therapeutic developmental pipeline of AlgiPharma ASs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
The report provides brief overview of AlgiPharma AS including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of AlgiPharma ASs human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement
Latest news and deals relating to the AlgiPharma ASs pipeline products
Reasons to buy
Evaluate AlgiPharma ASs strategic position with total access to detailed information on its product pipeline
Assess the growth potential of AlgiPharma AS in its therapy areas of focus
Identify new drug targets and therapeutic classes in the AlgiPharma ASs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of AlgiPharma AS and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain c